10月24日，Tempus AI盘中上涨5.09%，报67.06美元／股，成交额1.58亿美元。
消息面上，公司宣布与百时美施贵宝及Pathos AI达成多年战略合作，利用人工智能和患者数据推进阿尔茨海默病及其他神经系统疾病药物研发。
根据披露，在一项为期五年、总额5500万美元的协议下，Tempus将为Pathos开发覆盖数十万名神经疾病患者的去标识化数据集，供其通过Foundry AI平台开展疾病生物学、病程进展及临床试验设计研究。百时美施贵宝还将主导Pathos的E轮融资，并获得Foundry在其研发管线中的使用权限及神经科学项目三年独家权利。此次合作显示Tempus在医疗AI数据基础设施中的商业化延展继续推进。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.